Can a new biologic boost standard brain cancer therapy?

NCT ID NCT06147505

Ongoing Disease control Sponsor: Dushu Lake Hospital Affiliated to Soochow University Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial is testing whether adding an experimental drug called XS005 to the standard chemotherapy regimen (Stupp) is safe and shows promise for people with glioblastoma, an aggressive brain tumor. The study involves 13 adults aged 18 to 70 who will receive XS005 infusions over 16 weeks alongside their usual treatment. The main goals are to find the highest safe dose and to see if the combination may help slow tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: XS005 injection (an experimental biologic) combined with the standard Stupp chemotherapy regimen
What this could lead to: If successful, this could lead to a new treatment option that improves outcomes for people with glioblastoma, a type of brain cancer.
What could go wrong: This is an early-phase trial with only 13 participants, so results may not apply broadly. The main focus is safety, and the treatment may cause side effects or not effectively control the tumor.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUMOR

Contacts and locations

Locations

Dushu Lake Hospital Affiliated to Soochow University

Suzhou, Jiangsu, 215125, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.